The trial will evaluate the efficacy of psilocybin in Short-lasting Unilateral Neuralgiform Headache Attacks (SUNHA). The data is expected in early 2022
Research collaboration covers multiple antibody research programs
Sandoz is committed to building on its leading generic and biosimilar oncology portfolio to further expand patient access while contributing to the sustainability of healthcare systems
The company’s RenovoCath Delivery System designed for targeted treatment of solid tumours
Labetalol hydrochloride injection USP is indicated for the control of blood pressure in severe hypertension.
The global CRAMS segment is expected to clock 6.2% CAGR over CY21-26E to touch US $ 170 billion
Hetero’s drug is a biosimilar version of Roche’s Actemra/RoActemra and will be available at the end of this month
Metronidazole Gel USP, 1% is indicated for the topical treatment of inflammatory lesions of rosacea
The powder is approved for the treatment of adjunct therapy in moderate to severe Covid-19 patients
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
Subscribe To Our Newsletter & Stay Updated
